CVS Health Corporation

NYSE:CVS Stock Report

Market Cap: US$64.9b

CVS Health Valuation

Is CVS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CVS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$224.49
Fair Value
76.8% undervalued intrinsic discount
25
Number of Analysts

Below Fair Value: CVS ($52.14) is trading below our estimate of fair value ($224.49)

Significantly Below Fair Value: CVS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CVS?

Key metric: As CVS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CVS. This is calculated by dividing CVS's market cap by their current earnings.
What is CVS's PE Ratio?
PE Ratio13.1x
EarningsUS$5.02b
Market CapUS$64.90b

Price to Earnings Ratio vs Peers

How does CVS's PE Ratio compare to its peers?

The above table shows the PE ratio for CVS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.9x
CI Cigna Group
26x21.0%US$79.3b
LH Labcorp Holdings
45.6x22.4%US$19.6b
DGX Quest Diagnostics
20x11.7%US$17.1b
DVA DaVita
16.1x3.4%US$13.3b
CVS CVS Health
13.1x16.3%US$64.9b

Price-To-Earnings vs Peers: CVS is good value based on its Price-To-Earnings Ratio (13.1x) compared to the peer average (26.9x).

Price to Earnings Ratio vs Industry

How does CVS's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
THC Tenet Healthcare
4x-30.2%US$12.14b
NEUE NeueHealth
2.2xn/aUS$60.74m
IDXG Interpace Biosciences
0.8xn/aUS$4.23m
No more companies available in this PE range
CVS 13.1xIndustry Avg. 23.3xNo. of Companies11PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CVS is good value based on its Price-To-Earnings Ratio (13.1x) compared to the US Healthcare industry average (23.3x).

Price to Earnings Ratio vs Fair Ratio

What is CVS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CVS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.1x
Fair PE Ratio42x

Price-To-Earnings vs Fair Ratio: CVS is good value based on its Price-To-Earnings Ratio (13.1x) compared to the estimated Fair Price-To-Earnings Ratio (42x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CVS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$52.14
US$64.94
+24.5%
16.9%US$93.00US$48.01n/a25
Jan ’26US$44.89
US$66.26
+47.6%
16.2%US$93.00US$48.01n/a25
Dec ’25US$59.85
US$68.35
+14.2%
13.5%US$93.00US$57.00n/a25
Nov ’25US$55.81
US$69.46
+24.4%
14.4%US$93.00US$59.00n/a25
Oct ’25US$61.54
US$67.14
+9.1%
14.0%US$93.00US$59.00n/a25
Sep ’25US$57.24
US$67.26
+17.5%
13.0%US$93.00US$59.00n/a25
Aug ’25US$60.03
US$67.74
+12.8%
13.1%US$93.00US$58.00n/a25
Jul ’25US$58.15
US$69.10
+18.8%
13.4%US$93.00US$59.00n/a26
Jun ’25US$59.60
US$69.02
+15.8%
13.5%US$93.00US$59.00n/a26
May ’25US$56.31
US$84.69
+50.4%
10.8%US$101.00US$60.00n/a26
Apr ’25US$79.56
US$89.46
+12.4%
7.5%US$103.00US$77.00n/a26
Mar ’25US$73.84
US$89.74
+21.5%
7.0%US$103.00US$77.00n/a25
Feb ’25US$73.92
US$90.66
+22.6%
7.4%US$104.00US$80.00n/a24
Jan ’25US$78.96
US$88.41
+12.0%
8.6%US$104.00US$76.00US$44.8924
Dec ’24US$68.48
US$87.91
+28.4%
9.2%US$104.00US$76.00US$59.8523
Nov ’24US$68.73
US$90.19
+31.2%
10.4%US$110.00US$76.00US$55.8123
Oct ’24US$69.82
US$91.47
+31.0%
10.3%US$110.00US$76.00US$61.5424
Sep ’24US$65.67
US$92.31
+40.6%
9.8%US$110.00US$76.00US$57.2424
Aug ’24US$73.95
US$94.30
+27.5%
12.2%US$120.00US$72.00US$60.0323
Jul ’24US$69.13
US$99.33
+43.7%
16.6%US$143.00US$76.00US$58.1524
Jun ’24US$68.88
US$100.21
+45.5%
16.6%US$143.00US$76.00US$59.6023
May ’24US$73.89
US$109.18
+47.8%
13.3%US$143.00US$86.00US$56.3122
Apr ’24US$74.31
US$113.24
+52.4%
10.0%US$143.00US$95.00US$79.5621
Mar ’24US$82.47
US$114.05
+38.3%
9.4%US$143.00US$95.00US$73.8421
Feb ’24US$87.49
US$116.87
+33.6%
6.5%US$130.00US$100.00US$73.9223
Jan ’24US$93.19
US$118.40
+27.0%
4.9%US$130.00US$106.00US$78.9623
Analyst Price Target
Consensus Narrative from 25 Analysts
US$64.94
Fair Value
19.7% undervalued intrinsic discount
25
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 22:50
End of Day Share Price 2025/01/15 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CVS Health Corporation is covered by 62 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harshit GuptaAccountability Research Corporation
Christopher GrajaArgus Research Company
Samuel HudsonAtlantic Equities LLP